Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome

Journal of Infection

Volumn 62, Issue 3, 2011, Pages 240-243

  Guzmán Fulgencio, María ^a   Micheloud, Dariela ^a   Lorente, Raquel ^b   Bellón, Jose María ^b   de José Gomez, María Isabel ^b   Gurbindo, María Dolores ^b   León, Juan Antonio ^d   Muñoz Fernández, María Ángeles ^c   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C PEPTIDE; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LETTER; LIPID METABOLISM; LIPOATROPHY; LIPOTOXICITY; METABOLIC SYNDROME X; PHENOTYPE; STROKE;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; RISK ASSESSMENT;

EID: 79952149354     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.01.008     Document Type: Letter

References (12)

1. Villarroya F., Domingo P., Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta 2010, 1801(3):392-399.
2. Kotler D.P. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008, 49(Suppl. 2):S79-S85.
3. Krause J.C., Toye M.P., Stechenberg B.W., Reiter E.O., Allen H.F. HIV-associated lipodystrophy in children. Pediatr Endocrinol Rev 2005, 3(1):45-51.
4. Villarroya F., Domingo P., Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007, 31(12):1763-1776.
5. Hartman K., Verweel G., de Groot R., Hartwig N.G. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006, 25(5):427-431.
6. Martin S.S., Qasim A., Reilly M.P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008, 52(15):1201-1210.
7. Antuna-Puente B., Feve B., Fellahi S., Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34(1):2-11.
8. Gasic S., Tian B., Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 1999, 274(10):6770-6775.
9. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43(11):1271-1278.
10. Liang H., Yin B., Zhang H., Zhang S., Zeng Q., Wang J., et al. Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-alpha signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology 2008, 149(6):2943-2951.
11. Floris-Moore M., Fayad Z.A., Berman J.W., Mani V., Schoenbaum E.E., Klein R.S., et al. Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS 2009, 23(8):941-949.
12. Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170(2):191-203.